Management of refractory ascites and hepatorenal syndrome

Current Gastroenterology Reports

Volumn 13, Issue 1, 2011, Pages 17-25

  Sussman, Amy N ^a   Boyer, Thomas D ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Ascites; Cirrhosis; Hepatic hydrothorax; Hepatorenal syndrome; Hyponatremia; Midodrine; Octreotide; Refractory ascites; Renal failure; Terlipressin

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; ARGIPRESSIN; DIURETIC AGENT; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; PLACEBO; TERLIPRESSIN; TOLVAPTAN; VASOCONSTRICTOR AGENT;

ARTICLE; ASCITES; BACTERIAL PERITONITIS; CONTINUOUS INFUSION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DIURETIC THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; HEPATORENAL SYNDROME; HUMAN; HYDROTHORAX; HYPERKALEMIA; HYPERVOLEMIA; HYPONATREMIA; INFECTION PREVENTION; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; METABOLIC ACIDOSIS; ORTHOTOPIC TRANSPLANTATION; PARACENTESIS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; POSTOPERATIVE COMPLICATION; PROGNOSIS; RENAL REPLACEMENT THERAPY; SODIUM RESTRICTION; THORACOCENTESIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE KIDNEY INJURY; ASCITES; DIAGNOSIS, DIFFERENTIAL; DIURETICS; HEPATORENAL SYNDROME; HUMANS; HYDROTHORAX; HYPERTENSION, PORTAL; HYPONATREMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; PERITONITIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; RENAL REPLACEMENT THERAPY; VASOCONSTRICTOR AGENTS;

EID: 79551568748     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-010-0156-6     Document Type: Article

References (52)

1. R Planas S Montoliu B Balleste, et al. 2006 Natural history of patients hospitalized for management of cirrhotic ascites Clin Gastroenterol Hepatol 4 1385 94 10.1016/j.cgh.2006.08.007 17081806 (Pubitemid 44716742)
2. F Salerno C Camma M Enea, et al. 2007 Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data Gastroenterology 133 825 34 1:CAS:528:DC%2BD2sXhtFarsrfN 10.1053/j.gastro.2007.06.020 17678653 (Pubitemid 47374134)
3. P Gines A Cardenas 2008 The management of ascites and hyponatremia in cirrhosis Semin Liver Dis 28 43 58 1:CAS:528:DC%2BD1cXjvFCisr4%3D 10.1055/s-2008-1040320 18293276 (Pubitemid 351326532)
4. P Sort M Navasa V Arroyo, et al. 1999 Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med 341 403 9 1:CAS:528:DyaK1MXltlyltb8%3D 10.1056/NEJM199908053410603 10432325 (Pubitemid 29362513)
5. B Bernard J-D Grange EN Khac, et al. 1999 Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. A meta-analysis Hepatology 29 1655 61 1:CAS:528:DyaK1MXjvFOms7g%3D 10.1002/hep.510290608 10347104 (Pubitemid 29247035)
6. J Fernandez M Navasa R Planas, et al. 2007 Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis Gastroenterology 133 818 24 1:CAS:528:DC%2BD2sXhtFarsrfM 10.1053/j.gastro.2007.06.065 17854593 (Pubitemid 47374144)
7. P Angeli F Wong H Watson, et al. 2006 Hyponatremia in cirrhosis: results of a patient population survey Hepatology 44 1535 42 1:CAS:528: DC%2BD2sXislKktA%3D%3D 10.1002/hep.21412 17133458 (Pubitemid 44953659)
8. TD Boyer 2010 Tolvaptan and hyponatremia Hepatology 51 699 702 1:CAS:528:DC%2BC3cXisVGnsrY%3D 20101750
9. RW Schrier P Gross M Gheorghiade, et al. 2006 Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2099 2112 1:CAS:528:DC%2BD28Xht1Wqt7fO 10.1056/NEJMoa065181 17105757 (Pubitemid 44749318)
10. WR Kim SW Biggins WK Kremers, et al. 2008 Hyponatremia and mortality among patients waiting for liver transplantation N Engl J Med 359 1018 26 1:CAS:528:DC%2BD1cXhtVymurbF 10.1056/NEJMoa0801209 18768945
11. RM Strauss TD Boyer 1997 Hepatic hydrothorax Semin Liver Dis 17 227 232 1:STN:280:DyaK2svltlChug%3D%3D 10.1055/s-2007-1007200 9308127
12. TD Boyer Z Haskel 2005 AASLD Practice Guidelines: The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension Hepatology 41 386 400 10.1002/hep.20559 15660434 (Pubitemid 40165385)
13. Arroyo V, Gines P, Guevara M, Rodes J: Renal dysfunction in cirrhosis: pathophysiology, clinical features and therapy. In Hepatology: A textbook of liver disease, Ed. 5, Zakim D and Boyer TD eds, WB Saunders, 2006, p. 417-452.
14. L Tito P Gines V Arroyo, et al. 1990 Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites Gastroenterology 98 146 51 1:STN:280:DyaK3c%2Fns1yjsg%3D%3D 2293573
15. B Angermayr M Cejna F Koenig, et al. 2003 Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stent grafts versus bare stents Hepatology 38 1043 50 14512892
16. Nair S, Verma S, Thuluvath PJ: Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;1179-85. (Pubitemid 34454015)
17. TJ Weismuller J Prokein T Becker, et al. 2008 Prediction of survival after liver transplantation by pre-transplant parameters Scan J Gastroenterol 43 736 746 10.1080/00365520801932944 (Pubitemid 351868716)
18. RW Schrier V Arroyo M Bernardi, et al. 1988 Peripheral arterial vasodilaton hypothesis: a proposal for the initation of renal sodium and water retention in cirrhosis Hepatology 8 1151 7 1:STN:280:DyaL1czivF2mtQ%3D%3D 10.1002/hep.1840080532 2971015
19. P Ginès RW Schrier 2009 Renal failure in cirrhosis N Engl J Med 361 13 1279 1290 10.1056/NEJMra0809139 19776409
20. Y Iwakiri 2007 The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension J Clin Gastroenterol Suppl 3 S288 S294 10.1097/MCG.0b013e3181468b4c (Pubitemid 350059452)
21. PY Martin P Ginès RW Schrier 1998 Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis N Engl J Med 339 533 541 1:STN:280:DyaK1czmtlKltA%3D%3D 10.1056/NEJM199808203390807 9709047 (Pubitemid 28384887)
22. V Arroyo P Ginès AL Gerbes, et al. 1996 Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis Hepatology 23 164 176 1:STN:280:DyaK287jtlCmtQ%3D%3D 10.1002/hep.510230122 8550036
23. R Wiest S Das G Cadelina, et al. 1999 Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility J Clin Invest 104 1223 1233 1:CAS:528:DyaK1MXntVOgsrg%3D 10.1172/JCI7458 10545521
24. R Wiest G Garcia-Tsao 2005 Bacterial translocation (BT) in cirrhosis Hepatology 41 422 433 1:CAS:528:DC%2BD2MXisFCku7g%3D 10.1002/hep.20632 15723320 (Pubitemid 40289486)
25. A Albillos A de la Hera M González, et al. 2003 Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement Hepatology 37 208 217 1:CAS:528:DC%2BD3sXovVWgsg%3D%3D 10.1053/jhep.2003.50038 12500206 (Pubitemid 36042162)
26. R Fraces P Zapater M Gonzalez, et al. 2008 Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis Hepatology 47 978 985 10.1002/hep.22083 (Pubitemid 351449689)
27. R Bataller P Ginès M Guevara V Arroyo 1997 Hepatorenal syndrome Semin Liver Dis 17 233 247 1:CAS:528:DyaK2sXmtl2nsrY%3D 10.1055/s-2007-1007201 9308128
28. HM Wadeo ML Mai N Absan TA Gonwa 2006 Hepatorenal syndrome: pathophysiology and management Clin J Am Soc Nephrol 1 1066 10.2215/CJN.01340406
29. F Salerno A Gerbes P Ginès, et al. 2007 Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis Gut 56 1310 1318 1:CAS:528:DC%2BD2sXhtVKgsbbJ 17389705 (Pubitemid 47300435)
30. J MacAulay K Thompson BA Kibert, et al. 2006 Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction; are the equations for estimating renal function better? Can J Gastroenterol 20 521 526 16955148
31. KP Moore F Wong P Ginès, et al. 2003 The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club Heptatology 38 258 266 10.1053/jhep.2003.50315 (Pubitemid 36775818)
32. F Salerno A Gerbes P Gines, et al. 2007 Diagnosis, prevention, and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the International Ascites Club Gut 56 1310 1318 1:CAS:528:DC%2BD2sXhtVKgsbbJ 17389705
33. G Garcia-Tsao CR Parikh A Viola 2008 Acute kidney injury in cirrhosis Hepatology 48 2064 2077 1:CAS:528:DC%2BD1cXhsFams7%2FN 10.1002/hep.22605 19003880
34. P Angeli C Merkel 2008 Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis J Hepatol 48 Suppl 1 S93 S103 1:CAS:528:DC%2BD1cXjtlelsLc%3D 10.1016/j.jhep.2008.01.010 18304678
35. G Eknoyan 1974 Letter: renal disorders in hepatic failure Br Med J 2 670 1:STN:280:DyaE2c3ms1Cjuw%3D%3D 10.1136/bmj.2.5920.670-b 4835453
36. P Martin F Fabrizi 2008 Hepatitis C virus and kidney disease J Hepatol 49 613 624 1:CAS:528:DC%2BD1cXhtV2is77O 10.1016/j.jhep.2008.06.003 18662838
37. LL Gluud MS Kjaer E Christensen 2006 Terlipressin for hepatorenal syndrome Cochrane Database Sys Rev 4 CD005162
38. M Martin-Llahi MN Pepin M Guevara, et al. 2008 Terlipressin and albumin vs. Albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study Gastroenterology 134 1352 1359 1:CAS:528:DC%2BD1cXntVWhtLk%3D 10.1053/j.gastro.2008.02.024 18471512 (Pubitemid 351626950)
39. AK Sanyal T Boyer G Garcia-Tsao, et al. 2008 A randomized, prospective, double blind, placebo-controlled study of terlipressin for type I hepatorenal syndrome Gastroenterology 134 1360 1368 1:CAS:528:DC%2BD1cXntVWhtb8%3D 10.1053/j.gastro.2008.02.014 18471513 (Pubitemid 351615358)
40. C Duvoux D Zanditenas C Hézode, et al. 2002 Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome.: a pilot study Hepatology 36 374 380 1:CAS:528:DC%2BD38XmsVans7c%3D 10.1053/jhep.2002. 34343 12143045 (Pubitemid 34810356)
41. P Angeli R Volpin G Gerunda, et al. 1999 Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide Hepatology 29 1690 1697 1:CAS:528:DyaK1MXjvFOmsL4%3D 10.1002/hep.510290629 10347109 (Pubitemid 29247040)
42. E Esrailian ER Pantangco NL Kyulo, et al. 2007 Octreotide/midodrine therapy significnatly improves renal function and 30-day survival in patients with type I hepatorenal syndrome Dig Dis Sci 52 742 748 1:CAS:528: DC%2BD2sXhslWjtbg%3D 10.1007/s10620-006-9312-0 17235705
43. G Pomier-Layrargues SC Paquin Z Hassoun, et al. 2003 Octreotide in hepatorenal syndrome: a randomized, double-bline, placebo-controlled, crossover study Hepatology 1 238 243 10.1053/jhep.2003.50276 (Pubitemid 36775816)
44. C Alessandria O Ozdogan M Guevara, et al. 2005 MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation Hepatology 41 1282 1289 10.1002/hep.20687 15834937 (Pubitemid 40770280)
45. TA Gonwa GB Klintmalm M Levy, et al. 1995 Impact of pretransplant renal function on survival after liver transplantation Transplantation 59 361 365 1:STN:280:DyaK2M7ns1eluw%3D%3D 7871566
46. T Restuccia R Ortega M Guevara, et al. 2004 Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study J Hepatol 40 140 146 10.1016/j.jhep.2003.09.019 14672625 (Pubitemid 38064723)
47. LP Wong MP Blackley KA Andreoni, et al. 2005 Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy Kidney Int 1 362 370 10.1111/j.1523-1755.2005.00408.x (Pubitemid 43181396)
48. F Wong K Sniderman P Liu L Blendis 1997 The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt Gastroenterology 3 899 907 10.1053/gast.1997.v112.pm9041252 (Pubitemid 27113816)
49. M Guevara P Ginès JC Bandi, et al. 1998 Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems Hepatology 28 416 422 1:STN:280:DyaK1czlvFWktQ%3D%3D 10.1002/hep.510280219 9696006 (Pubitemid 28363668)
50. KA Brensing J Textor J Perz, et al. 2000 Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study Gut 47 288 295 1:STN:280: DC%2BD3cvgsVWjuw%3D%3D 10.1136/gut.47.2.288 10896924 (Pubitemid 30489776)
51. F Wong L Pantea K Sniderman 2004 Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type I hepatorenal syndrome Hepatology 40 55 64 1:CAS:528:DC%2BD2cXmtlSgtLc%3D 10.1002/hep.20262 15239086 (Pubitemid 38868923)
52. B Rasaratnam D Kaye G Jennings, et al. 2003 The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial Ann Intern Med 139 186 193 12899586